Virus-Like Particle Composition With Allergen-Tolerance Signals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune dysfunctions such as allergies are ineffective and can lead to severe reactions, and there is a need for a safe and long-term method to induce specific immune tolerance.
Innovation Solution
Virus-like particles (VLPs) are engineered to include an antigen and an immunoregulatory molecule on their surface, which modulate antigen-specific immune responses and induce specific immune tolerance by blocking activation of antigen-presenting cells and T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If desensitization methods consisting of progressive administration of allergens are used to induce specific immune tolerance, then immune tolerance may be induced, but severe allergic reactions including anaphylactic shock can occur and long-term effectiveness is limited
Solution Approach 1:
The patent uses virus-like particles as an intermediary carrier to deliver allergen peptides coupled with immunoregulatory molecules (such as CTLA-4 or PD-1). This intermediary structure enables controlled presentation of the allergen to the immune system while simultaneously providing immunosuppressive signals, thereby inducing tolerance without causing severe allergic reactions that occur with direct allergen administration
Solution Approach 2:
The invention creates a composite therapeutic agent by coupling allergen peptides with immunoregulatory molecules on the surface of virus-like particles. This composite structure combines the antigenic properties of the allergen with the immunosuppressive properties of molecules like CTLA-4 or PD-1, achieving both allergen-specific targeting and immune modulation in a single therapeutic entity
2Ease of operation
If conventional allergy treatments are administered to manage symptoms, then immediate relief may be provided, but no specific acting treatment is available for long-term management
Solution Approach 1:
The patent employs preliminary action by using virus-like particles to pre-condition the immune system through controlled exposure to coupled allergen-immunoregulatory complexes before challenging with the actual allergen. This preliminary immunomodulation establishes a state of tolerance that provides long-term protection rather than temporary symptom relief
Solution Approach 2:
The invention changes the fundamental parameters of allergy treatment by shifting from symptom management to immune system reprogramming. By modifying the immune response parameters through immunoregulatory molecules coupled to allergens on virus-like particles, the treatment achieves durable tolerance rather than transient symptom control
Data Source
AI summary
The invention relates to a virus-like particle comprising an allergen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an allergy.